EyeGene Inc is a Korea-based company primarily engaged in research and development in the medical and pharmaceutical fields. The Company is mainly engaged in the research and development of messenger ribonucleic acid (mRNA)-based vaccines. The Company also develops novel treatments for ophthalmic diseases, including treatments for macular degeneration and diabetic retinopathy, as well as adeno-associated virus (AAV) gene therapy targeting rare retinal diseases. In addition, the Company develops a quadrivalent meningococcal vaccine and recombinant botulinum toxin.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-09-09	₩2,065.00	-1.90%	60,848
26-09-09	₩2,105.00	+0.72%	108,591
26-09-08	₩2,090.00	+3.47%	198,902
26-09-07	₩2,020.00	+1.51%	100,647
26-09-04	₩1,990.00	+2.58%	105,383

End-of-day quote Korea S.E.

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. 2026-09-10			5-day change	1st Jan Change
2,065.00 ^KRW	-1.90%		+7.22%	+18.75%

09-04	MVRIX Co., Ltd. announced that it has received KRW 8 billion in funding from InterVest, Korea Investment Partners Co. Ltd., EyeGene Inc., Korea Omega Investment Corp, Lifecore Partners, SNU Technical Holdings	CI
25-09-16	Eyegene Inc to conduct capital increase of 32 billion won for operational funds	RE

Market Cap	89.27B 66.62M 57.32M 53.97M 49.18M 92.02M 6.34B 92.38M 640M 247M 3.23B 250M 245M 10.23B	P/E 2024	-5.71x	P/E 2025	-3.1x
Enterprise Value	44.33B 33.08M 28.47M 26.8M 24.42M 45.7M 3.15B 45.88M 318M 123M 1.6B 124M 122M 5.08B	EV / Sales 2024	11.6x	EV / Sales 2025	8.48x
Free-Float	70.86%	Yield 2024 *	-	Yield 2025	-

09-04	MVRIX Co., Ltd. announced that it has received KRW 8 billion in funding from InterVest, Korea Investment Partners Co. Ltd., EyeGene Inc., Korea Omega Investment Corp, Lifecore Partners, SNU Technical Holdings	CI
25-09-16	Eyegene Inc to conduct capital increase of 32 billion won for operational funds	RE
23-12-20	EyeGene Inc. announced that it has received KRW 15.000001688 billion in funding from BMI Korea Co., Ltd.	CI
23-12-12	EyeGene Inc. announced that it expects to receive KRW 15.000001688 billion in funding from BMI Korea Co., Ltd.	CI
23-05-15	EyeGene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
23-03-15	EyeGene Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
22-04-07	EyeGene Inc.(KOSDAQ:A185490) dropped from S&P Global BMI Index	CI
21-10-04	Maravai LifeSciences : Says Unit TriLink To Supply Proprietary Technology to EyeGene for Production of COVID-19 Vaccine	MT
21-09-20	EyeGene Inc.(KOSDAQ:A185490) added to S&P Global BMI Index	CI
20-09-17	EyeGene Inc. announced that it has received KRW 22 billion in funding from a group of investors	CI
20-09-15	EyeGene Inc. announced that it expects to receive KRW 22 billion in funding from a group of investors	CI
19-09-23	EyeGene Inc.(KOSDAQ:A185490) dropped from S&P Global BMI Index	CI
18-09-27	EyeGene Inc. announced that it has received KRW 29.9998664 billion in funding from Meritz Securities Co., Ltd., Investment Arm, IBK Capital Corporation, Korea Investment & Securities Co., Ltd., Investment Arm	CI

1 day	-1.90%
1 week	+7.22%
Current month	+8.23%
1 month	+23.28%
3 months	+41.44%
6 months	+48.56%
Current year	+18.75%

EyeGene Inc. Stock

Stocks

A185490

KR7185490000

Pharmaceuticals

Valuation : EyeGene Inc.

Chart: EyeGene Inc.

Latest news : EyeGene Inc.

Quotes and Performance

Price Extremes

Managers and Directors : EyeGene Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 week	1,935	2,165
1 month	1,779	2,305
Current year	1,182	2,805
1 year	1,182	2,915
3 years	1,182	4,895
5 years	1,182	48,000
10 years	1,182	60,200

Manager	Title	Age	Since
Suk-Keun Choi CEO	Chief Executive Officer	59	2024-02-19
Myeong-Jae Lee DFI	Director of Finance/CFO	57	2012-04-30
Won-Il Yoo PSD	President	63	2000-06-22

Director	Title	Age	Since
Won-Il Yoo BRD	Director/Board Member	63	2000-06-22
Myeong-Jae Lee BRD	Director/Board Member	57	2024-02-19
Dal-Hyun Kim BRD	Director/Board Member	64	2022-05-12

Date	Insider	Type	Main position	Quantity	% Market Cap.
4/10/24	Kwang-In Lee	Buy		8,019	0.0297%
4/10/24	Kwang-In Lee	Buy		12,297	0.0455%
3/12/24	Won-Il Yoo	Buy	Chairperson	1,000	0.0037%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EYEGENE INC.	-1.90%	+7.22%	-27.16%	-46.22%	67.91M
ELI LILLY AND COMPANY	+0.32%	-2.42%	+49.95%	+90.00%	1,002B
JOHNSON & JOHNSON	-0.19%	-4.05%	+51.98%	+64.25%	644B
ABBVIE INC.	+0.52%	-2.99%	+19.28%	+69.38%	443B
ROCHE HOLDING AG	-0.56%	-3.00%	+29.95%	+36.20%	343B
NOVARTIS AG	+0.65%	-14.39%	+11.59%	+27.30%	262B
ASTRAZENECA PLC	+2.03%	-3.06%	-1.18%	+12.11%	245B
AMGEN INC.	-2.02%	-13.70%	+37.62%	+46.45%	212B
NOVO NORDISK A/S	-0.90%	-5.06%	-18.47%	-58.14%	199B
GILEAD SCIENCES, INC.	-0.85%	-4.71%	+25.03%	+87.04%	181B
Average	-0.29%	-4.12%	+17.86%	+32.84%	352.98B
Weighted average by Cap.	+0.04%	-4.24%	+32.26%	+56.33%

	2024	2025
Net sales	3.36B 2.5M 2.15M 2.03M 1.85M 3.46M 238M 3.47M 24.05M 9.29M 121M 9.4M 9.2M 385M	3.57B 2.66M 2.29M 2.16M 1.96M 3.68M 253M 3.69M 25.56M 9.88M 129M 9.99M 9.78M 409M
Net income	-12.13B -9.05M -7.79M -7.33M -6.68M -12.5M -861M -12.55M -86.91M -33.59M -439M -33.98M -33.25M -1.39B	-15.71B -11.72M -10.09M -9.5M -8.65M -16.19M -1.12B -16.25M -113M -43.5M -568M -44.01M -43.05M -1.8B
Net Debt	-30.11B -22.47M -19.33M -18.2M -16.59M -31.03M -2.14B -31.16M -216M -83.38M -1.09B -84.36M -82.53M -3.45B	-44.94B -33.53M -28.86M -27.17M -24.76M -46.32M -3.19B -46.5M -322M -124M -1.63B -126M -123M -5.15B